- Home
- ISD vs MNPR Comparison
ISD vs MNPR Comparison
Compare ISD & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ISD | MNPR |
|---|---|---|
| Founded | 2012 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 488.5M | 403.4M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | ISD | MNPR |
|---|---|---|
| Price | $13.37 | $62.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $101.42 |
| AVG Volume (30 Days) | 94.6K | ★ 149.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 9.69% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.82 | $26.06 |
| 52 Week High | $14.79 | $105.00 |
Technical Indicators
Market Signals| Indicator | ISD | MNPR |
|---|---|---|
| Relative Strength Index (RSI) | 22.75 | 60.14 |
| Support Level | N/A | $50.92 |
| Resistance Level | $14.67 | $89.51 |
| Average True Range (ATR) | 0.19 | 3.16 |
| MACD | -0.12 | 1.20 |
| Stochastic Oscillator | 12.33 | 83.13 |
Price Performance
Historical ComparisonAbout ISD PGIM High Yield Bond Fund Inc.
PGIM High Yield Fund Inc is a diversified, closed-end management investment company, active in the financial services domain. The fund's primary investment objective is to provide a high level of current income, with its secondary objective being capital appreciation. It invests at least eighty percent of its investable assets in a diversified portfolio of high-yield fixed-income instruments that are rated below investment grade with varying maturities and other investments.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.